On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives–the first such product cleared there for patients who don't respond to antihistamines alone.
written on 07.03.2014
On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives–the first such product cleared there for patients who don't respond to antihistamines alone.
See our Cookie Privacy Policy Here